Clinical Study on Rosiglitazone Monotherapy of Early Type 2 Diabetes / 中国药房

ABSTRACT

OBJECTIVE:To evaluate the efficacy and safety of domestic rosiglitazone monotherapy in newly diagnosed patients whose type 2 diabetes is inadequately controlled.METHODS:In a double-blind,randomized,with placebo controlled phase Ⅱ clinical trial,patients were assigned to receive 4mg/d of rosiglitazone(n=27) or placebo(n=27) for 8 weeks.RESU-LTS & CONCLUSION:Fasting and postprandial plasma glucose levels of the rosiglitazone group decreased by 27.1% and 55.7%,and fasting and postprandial plasma glucose levels of the control group decreased by 10.6% and 19.8% respectively.These changes of fasting and postprandial plasma glucose levels in the rosiglitazone group were significantly higher than those in the placebo group(P